Fig. 2: In vivo synthesis of defective viruses significantly enhances therapeutic efficacy against B16F10 melanoma.
From: Cascade amplification of therapeutic payloads for cancer immunotherapy
Six- to eight-week-old C57BL/6 mice (n = 5 per group, a cage of animal) were subcutaneously inoculated with 1 million B16F10 melanoma cells. Seven days post-inoculation, mice were intratumorally treated with PBS (Control group of basal line), or LNP encapsulating 10 µg SamRNA encoding with mouse IL-12 (IL-12) and 1 µg modified mRNA encoding with firefly luciferase (Control group of treated group) or LNP encapsulated 10 µg of SamRNA encoding IL-12 and 1 µg modified mRNA encoding capsids/envelops from VEE. Results are shown as: Tumor areas (Y-axis), Survival rates (Y-axis), and Body weight changes (Y-axis) versus days post-B16F10 melanoma cell inoculation (X-axis) a, b, and c, respectively. The P-Values label in b were determined by a Comparison of Survival Curves (Kaper-myer) test.
